Click on image to enlarge.
Increased ETA receptor signaling in the kidney is associated with progression of IgAN1
Explore the Pathogenesis of IgAN
Watch this video to discover the mechanism of disease of IgAN, a heterogeneous glomerular disease.
IgAN is Characterized by a Multi-hit Disease Model1
In Hit 4, overactivation of the endothelin and complement systems contributes to the progression of IgAN1
In Hit 4, overactivation of the endothelin and complement systems contributes to the progression of IgAN1
These processes may lead to proteinuria, inflammation, and fibrosis, which can cause progressive kidney damage1
C3a, complement 3a; C3b, complement 3b; C5, complement 5; ET-1, endothelin-1; ETA, endothelin A; IgA1, immunoglobulin A1; MAC, membrane attack complex.
References: 1. Kohan DE, Barratt J, Heerspink HJL, et al. Targeting the endothelin A receptor in IgA nephropathy. Kidney Int Rep. 2023;8:2198-2210. doi:10.1016/j.ekir.2023.07.023 2. Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol. 2019;10:504. doi:10.3389/fimmu.2019.00504 3. Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1 4. Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol. 2018;40(1):125-140. doi:10.1007/s00281-017-0655-8 5. Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol. 2018;102:89-119. doi:10.1016/j.molimm.2018.06.008
References: 1. Kohan DE, Barratt J, Heerspink HJL, et al. Targeting the endothelin A receptor in IgA nephropathy. Kidney Int Rep. 2023;8:2198-2210. doi:10.1016/j.ekir.2023.07.023 2. Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol. 2019;10:504. doi:10.3389/fimmu.2019.00504 3. Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1 4. Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol. 2018;40(1):125-140. doi:10.1007/s00281-017-0655-8 5. Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol. 2018;102:89-119. doi:10.1016/j.molimm.2018.06.008